These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12795242)

  • 41. Simplified procedure for efficient and unbiased population size estimation.
    Cruz M; González-Villa J
    PLoS One; 2018; 13(10):e0206091. PubMed ID: 30372479
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.
    Ette EI; Kelman AW; Howie CA; Whiting B
    Ann Pharmacother; 1993 Sep; 27(9):1034-9. PubMed ID: 8117353
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Automated covariate model building within NONMEM.
    Jonsson EN; Karlsson MO
    Pharm Res; 1998 Sep; 15(9):1463-8. PubMed ID: 9755901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of some practical sampling strategies for population pharmacokinetic studies.
    Jonsson EN; Wade JR; Karlsson MO
    J Pharmacokinet Biopharm; 1996 Apr; 24(2):245-63. PubMed ID: 8875349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonparametric density estimation applied to population pharmacokinetics.
    Claret L; Iliadis A
    Math Biosci; 1996 Apr; 133(1):51-68. PubMed ID: 8868572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models.
    Rosner GL; Müller P
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):209-33. PubMed ID: 9408860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sample size computations for PK/PD population models.
    Kang D; Schwartz JB; Verotta D
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):685-701. PubMed ID: 16284914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
    Bauer RJ; Guzy S; Ng C
    AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of simulated annealing for finding optimal population designs.
    Duffull SB; Retout S; Mentré F
    Comput Methods Programs Biomed; 2002 Jul; 69(1):25-35. PubMed ID: 12088590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.
    Siripuram VK; Wright DFB; Barclay ML; Duffull SB
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):415-423. PubMed ID: 28612141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.
    Dokoumetzidis A; Aarons L
    J Biopharm Stat; 2007; 17(5):851-67. PubMed ID: 17885870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The importance of modeling interoccasion variability in population pharmacokinetic analyses.
    Karlsson MO; Sheiner LB
    J Pharmacokinet Biopharm; 1993 Dec; 21(6):735-50. PubMed ID: 8138894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Balanced designs in longitudinal population pharmacokinetic studies.
    Ette EI; Sun H; Ludden TM
    J Clin Pharmacol; 1998 May; 38(5):417-23. PubMed ID: 9602953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
    Bazzoli C; Retout S; Mentré F
    Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A semiparametric method for estimating population size for capture-recapture experiments with random covariates in continuous time.
    Yip PS; Lin HZ; Xi L
    Biometrics; 2005 Dec; 61(4):1085-92. PubMed ID: 16401282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The interval testing procedure: A general framework for inference in functional data analysis.
    Pini A; Vantini S
    Biometrics; 2016 Sep; 72(3):835-45. PubMed ID: 26811864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2010 Sep; 20(5):1026-42. PubMed ID: 20721789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Model choice problems using approximate Bayesian computation with applications to pathogen transmission data sets.
    Lee XJ; Drovandi CC; Pettitt AN
    Biometrics; 2015 Mar; 71(1):198-207. PubMed ID: 25303085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.